|
|
Главная |
07.09.2016 |
|
07.09.2016 |
LUGANO, 6 SEPTEMBER, 2016 – Professor Sumitra Thongprasert has been awarded the second ESMO Women for Oncology award1, honouring her position as a role model for women in the profession and for her distinguished career.
This is the second year of the ESMO Women for Oncology award, which was established to acknowledge an individual who has significantly supported the career development of women in oncology.
Prof. Thongprasert has held many important positions in the Far East and internationally. Currently she is the Emeritus Professor at the Faculty of Medicine, Chiang Mai University, and also Director of the Centre of Excellence in Cancer at Bangkok Hospital Chiang Mai, Thailand.
Prof. Thongprasert began her career with a fellowship in haematology-oncology at the Memorial Sloan-Kettering Cancer Centre in New York, after which she returned to Chiang Mai University in Thailand and set up the Medical Oncology Unit. She served as Professor of Oncology at the Faculty of Medicine, Chiang Mai University from 1999–2012. |
Продолжение...
|
|
07.09.2016 |
Lugano, Switzerland, 6 September 2016 -- The European Society for Medical Oncology (ESMO), the leading professional organisation for medical oncology, has revealed the four outstanding recipients of its distinguished awards.
Alberto Sobrero receives the ESMO Award for his world renowned research on treatment of gastrointestinal cancer.1
“Prof. Sobrero has not only very broadly and prominently co-authored more than 200 original contributions on very important issues mainly relevant to colorectal cancer where he is considered a leading world expert, but has also cooperated to a large extent within the European Society for Medical Oncology,” said Christoph Zielinski, Chair of the ESMO Fellowship and Award Committee, comprised of oncology leaders who select exceptional international researchers and clinicians for recognition.
Commenting on the significance of receiving the honour, Sobrero said: “One always wonders if he is doing well in his professional life: the ESMO Award is certainly the best answer to this questioning.” |
Продолжение...
|
|
|
22.08.2016 |
 Актуальность
У отобранных пациентов с односторонним, ограниченным пределами органа раком предстательной железы (РПЖ) гемиаблация поражённой доли может быть адекватным способом достижения приемлемых онкологических результатов с меньшим числом осложнений.
Цель исследования
Оценить онкологические и функциональные результаты фокальной высокоинтенсивной фокусированной ультразвуковой (HIFU) гемиаблации при одностороннем РПЖ, ограниченном пределами органа. |
Продолжение...
|
|
22.08.2016 |
 Актуальность
Недавно была задокументирована взаимосвязь между некоторыми из 23 мононуклеотидных полиморфизмов, открытых за последнее время с помощью чипа iCOGS (Совместное онкологическое генетически-средовое исследование - COGS), указывающих на риск рака предстательной железы (РПЖ), и аспектами агрессивности этого заболевания. Нужно определить применимость этих iCOGS-МНП в протоколе активного наблюдения (АН).
Цель исследования
Определить взаимосвязь между iCOGS-МНП и снижением степени дифференцировки у мужчин, подвергшихся хирургическому лечению и АН по поводу РПЖ низкого риска.
Дизайн, условия и участники исследования
Генотипы 23 iCOGS-МНП были определены у пациентов европеиодной расы с суммой баллов Глисона (СГ) в биопсийном материале, равной 6, включая 950 мужчин, подвергшихся куративному хирургическому лечению, и 209 мужчин, выбравших АН. Клинические и патоморфологические характеристики были документированы у всех пациентов. |
Продолжение...
|
|
22.08.2016 |
 Контекст
Руководство Европейской ассоциации урологов по мышечно-неинвазивному раку мочевого пузыря (МНИРМП) рекомендует проводить немедленную однократную инстилляцию химиотерапевтического препарата после трансуретральной резекции мочевого пузыря (ТУРМП) всем пациентам с низким и промежуточным онкологическим риском, но эта рекомендация остаётся спорной.
Цель
Определить, какие пациенты с МНИРМП получат пользу от немедленной однократной инстилляции.
Сбор материала
Был выполнен систематический обзор и мета-анализ индивидуальных данных пациентов (ИДП) из рандомизированных исследований по сравнению эффективности однократной инстилляции после ТУРМП с одной лишь ТУРМП при МНИРМП.
|
Продолжение...
|
|
22.08.2016 |
|
Последнее обновление ( 22.08.2016 )
|
Продолжение...
|
|
17.08.2016 |
Dear Aleksandr Shulyak,
The highly anticipated 3rd ESU Masterclass on Lasers in Urology will take place from 3-4 November in Barcelona, Spain. Spaces for the masterclass are limited and the deadline for applications is fast approaching! Kindly register on or before 2 September 2016. Here are top three reasons why you shouldn't miss it: |
Продолжение...
|
|
12.08.2016 |
|
|
 |
Enjoy Buenos Aires & Earn CME Credits! |
|
01.08.2016 |
|
01.08.2016 |
|
Последнее обновление ( 01.08.2016 )
|
Продолжение...
|
|
01.08.2016 |
ESMO, the leading European professional organisation for medical oncology, has announced that the ESMO 2018 Annual Congress will take place between 19-23 October 2018 at the Messe Muenchen, Germany.
The ESMO Congress is the appointment in Europe for clinicians, researchers, patient advocates, journalists and the pharmaceutical industry from all over the world to get together, learn about the latest advances in oncology and translate such progress into better cancer patient care.
“Germany has a long-standing tradition of active participation in ESMO’s activities. This is witnessed by the high number of German members, ranking third after the USA and Italy, as well as their ever growing attendance at our events,” says ESMO President Fortunato Ciardiello. “Our German colleagues cover many seats in various ESMO committees, in the ESMO Faculty as well as on the ESMO Executive Board, demonstrating the contribution Germany makes to the oncology field and to ESMO. I am pleased that Germany – and in particular Munich, will be our destination in 2018.” |
Продолжение...
|
|
|
01.08.2016 |
LUGANO, 26 July 2016 – A major new study has found substantial differences in the formulary availability, out-of-pocket costs and actual availability of anti-cancer medicines across Europe. The ESMO European Consortium Study on the Availability of Anti-Neoplastic Medicines is published today in the August issue of Annals of Oncology (1).
This ESMO initiated survey which gathered data from 46 European countries was carried out in cooperation with researchers from the Union for International Cancer Control (UICC), the Institute of Cancer Policy of King’s College London and the European Society of Oncology Pharmacy (ESOP). |
Продолжение...
|
|
25.07.2016 |
|
|
25.07.2016 |
|
|
 |
Durante sólo dos días, el 9 y el 10 de julio, |
todos los que se registren al Congreso |
SIU 2016 pagarán la tarifa reducida de |
país anfitrión. |
|
€200 |
Residentes, personal médico en |
|
formación y para enfermeros |
|
Продолжение...
|
|
20.07.2016 |
Bringing confidence to decision making in breast cancerRecent studies in genomic testing are giving us confidence for deciding if breast cancer patients will benefit from having chemotherapy.
 Prospective phase 3 PlanB trial of 21-gene Recurrence Score® result in breast cancerBy Oleg Gluz, MDWatch |
Последнее обновление ( 20.07.2016 )
|
Продолжение...
|
|
19.07.2016 |
LUGANO, 7 July 2016 – Details of the first study by one of Europe’s largest cancer centres, the Medical University of Vienna (MUV), assessing the clinical impact and feasibility of the ESMO Magnitude of Clinical Benefit Scale (MCBS) in a real-life context are now available on ESMO Open(1).
By systematically evaluating well-established oncologic treatment strategies from first-line to salvage treatment throughout major tumour entities, the MUV team’s results show that the ESMO-MCBS works very reliably and reproducibly in the field of advanced or metastatic disease and encourages its use in daily routine.
|
Продолжение...
|
|
19.07.2016 |
To mark the publication of the ESMO European Consortium Study on the Availability of Anti-Neoplastic Medicines, ESMO President Elect Josep Tabernero will lead a virtual press conference alongside two of the study’s authors (Alexandru Eniu and Nathan Cherny) to discuss its findings and its role in making progress towards achieving sustainable cancer care for all patients.
Click here to pre-register for this online event taking place at
|
Продолжение...
|
|
12.07.2016 |
Guidelines reflect personalized treatment approach
LUGANO, 06 July 2016 – ESMO, the leading European professional organisation for medical oncology, has released new consensus guidelines for the management of metastatic colorectal cancer that reflect an increasingly personalized approach to treatment, as published online today in Annals of Oncology(1).
“Management of metastatic colorectal cancer is becoming more complex, requiring a strategic approach and evidence-based patient selection for the best treatment options,” said chair of the ESMO Consensus Conference Professor Eric Van Cutsem, from the University Hospitals Gasthuisberg/Leuven and KU Leuven, Belgium. |
Продолжение...
|
|
12.07.2016 |
Phase III trial finds excellent safety and tolerability
BARCELONA-LUGANO, 02 July 2016 – A novel anti-interleukin 1-alpha antibody has shown a significant impact on symptoms, and a high level of safety and tolerability in patients with advanced colorectal cancer, according to phase III data (1) presented at the European Society for Medical Oncology’s 18th World Congress of Gastrointestinal Cancer in Barcelona, Spain.
Xilonix is the first monoclonal antibody immunotherapy to specifically target and neutralize interleukin-1 alpha (IL-1α), one of the most potent inflammatory substances manufactured by the body or tumour cells.
“IL-1α in tumours promotes angiogenesis, helping to provide crucial blood supply for tumour growth, and it can also send the body’s metabolism out of control, causing it to burn muscle and lose weight,” said lead investigator Dr Tamas Hickish. At the same time, IL-1α effects on the brain can cause the fatigue, anxiety and anorexia associated with advanced cancer. |
Продолжение...
|
|
12.07.2016 |
|
12.07.2016 |
|
Dear Prof. Aleksandr Shulyak,
Europe’s biggest urological event is coming to London next year! From 24 to 28 March 2017, the London ExCel will host the 32nd Annual EAU Congress (EAU17).
Preparations are already in full swing and as of today you can contribute to one of the most comprehensive scientific programmes in the field of urology. The EAU17 abstract submission is now open!
How to submit your abstract?
You can submit your abstract via the online abstract submission system. Faxed, e-mailed or mailed abstracts will not be accepted. Carefully read the Abstract submission rules and regulations before submitting your abstract.
|
|
|
|
Продолжение...
|
|
12.07.2016 |
Phase III trial confirms efficacy and safety of new second-line agent
BARCELONA-LUGANO, 30 June 2016 – Oral multikinase inhibitor regorafenib achieves significantly improved survival rates compared to placebo in patients with hepatocellular carcinoma, according to data from the phase III RESORCE trial (1), presented at the ESMO 18th World Congress of Gastrointestinal Cancer in Barcelona, Spain.
“Systemic treatment for hepatocellular carcinoma has long consisted of just one agent - sorafenib –which was shown to provide a significant improvement in life expectancy almost 10 years ago, but no other agent has surpassed its benefits,” said the study’s principal investigator Dr Jordi Bruix, Head of the BCLC group at the Hospital Clínic and Scientific Director of the Network for Biomedical Research for Hepatic and Digestive Diseases (CIBEREHD). |
Продолжение...
|
|
07.07.2016 |
BARCELONA-LUGANO, 29 June 2016 – Anti-PD-L1 immunotherapy may achieve a response in patients with microsatellite-stable metastatic colorectal cancer if combined with a MEK inhibitor, according to phase I data presented at the ESMO 18th World Congress of Gastrointestinal Cancer in Barcelona, Spain.
“So far, immunotherapy has only shown activity in patients with microsatellite instability-high colorectal cancer, which is only 5% of the population,” says the study’s (1) principal investigator Dr Johanna Bendell, from the Sarah Cannon Research Institute and Tennessee Oncology, in Nashville, Tennessee.
Microsatellite instability-high colorectal cancers are associated with a greater number of mutations and are therefore more responsive to immunotherapy with PD-L1/PD-1 blockade. However the majority of patients with metastatic colorectal cancer – around 95% - have microsatellite-stable disease that so far has shown almost no response to immunotherapy. |
Продолжение...
|
| |
Еще...
-
Отчет - НМАПО
-
Urology Week 2016
-
Отчет Института урологии
-
Your mid-month EAU News Update!
-
Конференція «Сучасні технології в урології»
-
MEDIA ALERT - ESMO 2016: From disease treatment to patient care
-
Endoscopic Diagnosis and Treatment in Urinary Bladder Pathology
-
CEM in Vienna: Last Call for Abstracts
-
Improve your skills in Endourology and Laparoscopy at ESUT16
-
Your EAU News Update - June
-
SIU 2016: SNEAK PEEK!
-
Study Suggests Chemotherapy After Radical Prostatectomy May Benefit Men Who Are At High Risk for Relapse
-
Tele-Urology Improves Access and Quality of Care for Patients
-
Projected Climate Change and Rise in Obesity Levels Expected to Increase Burden of Stone Disease
-
ERUS16: SUBMIT YOUR ABSTRACT BEFORE JUNE 1ST!
-
PROJECTED CLIMATE CHANGE AND RISE IN OBESITY LEVELS EXPECTED TO INCREASE BURDEN OF STONE DISEASE
-
UROLOGIC SURGICAL PATHOLOGY. EXPERT CONSULT - ONLINE AND PRINT. EDITION NO. 3
-
STREAM OF MLUTS COURSE: TEST YOUR KNOWLEDGE TODAY
-
NTERNATIONAL SURVEY FOR VRE PREVENTION
-
МІЖРЕГІОНАЛЬНОЇ НАУКОВО-ПРАКТИЧНОЇ КОНФЕРЕНЦІЇ «АКТУАЛЬНІ ПИТАННЯ СУЧАСНОЇ УРОЛОГІЇ, ОНКОУРОЛОГІЇ, СЕКСОПАТОЛОГІЇ ТА АНДРОЛОГІЇ»
-
HEINE H. HANSEN AWARD GOES TO SURESH SENAN
-
THE JOURNAL OF UROLOGY: APR-2016 (VOLUME 195, ISSUE 4)
-
OSIMERTINIB GIVEN AS FIRST-LINE TREATMENT MAY ALTER BIOLOGY OF EGFR MUTATED NSCLC
-
IMMUNOTHERAPY WITH LIVE BACTERIUM IMPROVES RESPONSE RATE IN MALIGNANT PLEURAL MESOTHELIOMA
-
ПРОГРАМА НАУКОВО - ПРАКТИЧНОЇ КОНФЕРЕНЦІЇ «АКТУАЛЬНІ ПИТАННЯ СУЧАСНОЇ СЕКСОЛОГІЇ ТА АНДРОЛОГІЇ » 19.05.2016
-
PATIENTS WITH EGFR EXPRESSING NSCLC BENEFIT MOST FROM NECITUMUMAB ADDED TO CHEMOTHERAPY
-
ПРОГРАМА КОНГРЕСУ АСОЦІАЦІЇ УРОЛОГІВ УКРАЇНИ 21 – 23 КВІТНЯ 2016 РОКУ, УКРАЇНА, М.КИЇВ
-
NEW! UROwebinar - Update on Bladder Cancer Management
-
6th International Meeting Challenges in Endourology, 29-31 May 2016, Paris, France
-
Press release, European Association of Urology RNA sequencing opens door to accurate, highly specific test for prostate cancer
-
Men who choose active surveillance instead of radiotherapy or surgery for low-risk prostate cancer have similar Quality of Life as men without cancer
-
Press release, European Association of Urology Study shows patients prefer iPads to doctors when discussing surgery
-
Press release, European Association of Urology Study finds kidney transplant donation rates vary widely across Europe
-
Press release, European Association of Urology Can we predict aggressiveness of prostate cancer before surgery with a blood test?
-
Press release, European Association of Urology How a bad night’s sleep might worsen cancer development
-
EAU16 - Sunday 13 March 2016: Highlights from Day 3
-
EAU16 - SATURDAY 12 MARCH 2016: HIGHLIGHTS FROM DAY 2
-
НАУКОВИЙ СИМПОЗІУМ «АКТУАЛЬНІ ПИТАННЯ ДИТЯЧОЇ УРОЛОГІЇ»
-
EAU INTERNATIONAL RELATIONS NEWSLETTER: WHAT ARE YOUR NEW YEARS’ RESOLUTIONS?
-
LAST CHANCE TO REGISTER FOR THE LATE FEE FOR EAU16!
-
SIU-WJU ARTICLE OF THE MONTH SERIES - FEBRUARY 2016
-
INTERNATIONAL CONFERENCE MEETING, APRIL 25TH TO 30TH, 2016. DALLAS, TEXAS USA
-
EAU NEWS UPDATE - FEBRUARY
-
КОНГРЕСС АССОЦИАЦИИ УРОЛОГОВ УКРАИНЫ
-
КОНФЕРЕНЦИИ «МАЛОИНВАЗИВНЫЕ ТЕХНОЛОГИИ В УРОЛОГИИ -2016»
-
BLADDER CANCER
-
EAU Research Foundation Session, 12 March - 14.45 – 17.00 hrs - EAU16 (Munich)
-
6TH HISTORY CONGRESS AT EAU16: MEET THE PIONEERS OF UROLOGY
-
EAU News – Looking back at 2015 and ahead to EAU16
-
Активное наблюдение при раке предстательной железы: систематический обзор роли клиникоморфологических переменных и биомаркеров в стратификации риска
-
Систематический обзор и мета-анализ клинической эффективности ударноволновой литотрипсии, ретроградной интраренальной хирургии и перкутанной нефролитотомии при камнях нижнего полюса почки
-
Объем лимфаденэктомии не влияет на выживаемость пациентов с почечно-клеточным раком и метастазами в лимфатические узлы: статистические ошибки, связанные с обработкой «отсутствующей информации»
-
Систематический обзор и мета-анализ сравнительной клинической эффективности биполярной и монополярной трансуретральных резекций простаты
-
Отведение мочи после радикальной цистэктомии по поводу рака мочевого пузыря: варианты отведения, выбор пациентов и послеоперационные результаты
-
Лечение кистозного поражения почек. Обзор литературы.
-
УЗИ кистозной дисплазии почек: необходимо ли подтверждение при радиоизотопной ренографии?
-
Роль самостоятельного бужирования в лечении стеноза уретры
-
Роль эндопиелотомии в практике детских урологов при коррекции сужений лоханочно-мочеточникового сегмента
-
Влияние растительного препарата Канефрон® Н на результаты дистанционной ударно-волновой литотрипсии
-
Местная эстрогенотерапия в урологии
-
Длительность нейрогенного мочевого пузыря и эффективность первой инъекции ботулотоксина
-
Выраженность гематурии после оперативного лечения уролитиаза: роль индивидуальной реактивности тромбоцитов на агонисты
-
Инфекции мочевых путей: Экономическое влияние употребления воды
-
ESOU16: Last chance to register
-
EAU NEWS - NOVEMBER: MULTIDISCIPLINARITY AND THE NEW EU FOCUS
-
GET A GLIMPSE OF THE SCIENTIFIC PROGRAMME FOR EAU16!
-
EUROPEAN MEDICAL JOURNAL UROLOGY UPDATES
-
Аптечная сеть США исключила «Виагру» из списка препаратов, подлежащих лекарственному страхованию
-
EUROPEAN MEDICAL JOURNAL ONCOLOGY & HEMATOLOGY UPDATES
-
SEEC 2015 NEWSLETTER
-
THE EUROPEAN ASSOCIATION OF UROLOGY (EAU) LAUNCHES VIRTUAL EUROPEAN MUSEUM OF UROLOGY
-
THANK YOU FOR JOINING US DOWN UNDER!
-
МикроРНК и метилирование ДНК как эпигенетические регуляторы митоза, мейоза и спермиогенеза
-
Одномоментное лечение сложного нефролитиаза
-
Риск прободения прямой кишки при использовании трансректального УЗ датчика во время лазерной фотовапоризации предстательной железы. Описание 4-х случаев.
-
ESOU16: REGISTER BEFORE NOVEMBER 1ST FOR THE EARLY REGISTRATION FEE!
-
WE WILL ADDRESS THE BIOINFORMATICS CHALLENGES FOR YOU
-
ISC NOVEMBER NEWSLETTER
-
Школа по диагностике и лечению рака почки
-
European Medical Journal Nephrology Updates
-
Приглашаем принять участие в конференциях Польской ассоциации урологов
-
Разработана модель оценки генетического риска рака предстательной железы
-
PSMA-617 – перспективный метод диагностики и лечения рака предстательной железы
-
Can't Make the 2015 SIU congress in Melbourne? Be There Virtually
-
Atezolizumab set to change refractory lung cancer treatment
-
Six new countries join the list of ESMO Designated Centres of Integrated Oncology and Palliative Car
-
EAU News - You can still register for our autumn meetings
-
Migrants, refugees and neglected patients: nationality and social status affect cancer care quality
-
International agreement on how to evaluate prostate cancer MRI-scans “likely to change how we detect prostate cancer”
-
Клиническая больница МЕДСИ г. Отрадное. Онлайн-трансляция операции по урологиив 3D
-
Послеоперационный инфекционный симфизит
-
Опухоль более 7 см. Влияние размера опухоли почки на результаты частичной нефрэктомии
-
Минимально инвазивные петлевые операции у больных, страдающих недержанием мочи
-
mHealth – новые возможности развития телекоммуникационных технологий в здравоохранении
-
Бариатрические операции способствуют снижению риска развития недержания мочи
-
Submit your abstract for EAU16 in Munich!
-
НАУКОВО-ПРАКТИЧНА КОНФЕРЕНЦІЯ з міжнародною участю «СУЧАСНІ МЕТОДИ ДІАГНОСТИКИ ТА ЛІКУВАННЯ В УРОЛОГІЇ, АНДРОЛОГІЇ ТА ОНКОУРОЛОГІЇ»
-
Preliminary programme 15th CEM in Budapest
-
Submit your research
-
Freely accessible research on castration resistant prostate cancer
| << В начало < Предыдущая 1 2 3 4 5 6 7 Следующая > В конец >>
| Всего 253 - 378 из 835 | |
|
|
|
Ukraine.UroWeb.ru - Український інформаційний портал урологів (Украинский информационный портал урологов) © 2021
|
| | | | | | | | | | | |
| | |
| |